FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria di Stack

Triple GH Stack

GH Optimizationadvanced

88

sintesi

88
Share
Peptidi

3

Media giornaliera mcg

957

Livello

advanced

Aggiunto

May 17, 2026

Panoramica

The Triple GH Stack amplifies the classic CJC-1295 + Ipamorelin protocol with Sermorelin, adding a third GHRH-pathway stimulant to maximize pituitary priming and increase the duration of GH stimulation beyond what CJC-1295 alone provides. Sermorelin is the shortest functional GHRH analog — a 29-amino acid truncated version of native GHRH. Where CJC-1295 provides a longer-acting GHRH signal, Sermorelin provides a more physiologically rapid, native-pattern pulse. Together they create a layered stimulation pattern: Sermorelin fires first with a sharp, natural signal, while CJC-1295 extends and sustains the pituitary response over a longer window. Ipamorelin continues to provide ghrelin-pathway amplification, ensuring the pituitary primed by CJC-1295 and Sermorelin releases its maximum GH payload with each pulse. The result is higher peak GH secretion and more frequent physiological pulses throughout the day and night. The 5-days-on/2-days-off cycling on Sermorelin (typically weekdays, off weekends) preserves receptor sensitivity on the GHRH pathway and prevents the tachyphylaxis that can occur with continuous stimulation. This stack is used by advanced practitioners seeking maximum GH axis stimulation without exogenous HGH. Blood work monitoring (IGF-1, fasting glucose) every 6–8 weeks is essential.

Protocollo di Dosaggio

CJC-1295

Every day· subcutaneous

Leggi di più su CJC-1295 →

300 mcg

per dose

Ipamorelin

Every day· subcutaneous

Leggi di più su Ipamorelin →

300 mcg

per dose

Sermorelin

5 days on/2 off· subcutaneous

Leggi di più su Sermorelin →

500 mcg

per dose

Obiettivi & Evidenze

Maximum GH outputAnti-agingBody compositionLean muscleRecovery
Livello di Evidenza:Dati umani

Avvertenze

  • Multi-GHRH stacking increases risk of pituitary receptor downregulation. Cycle carefully and monitor IGF-1 levels.

Comments

Sign in to join the discussion

Avvertenza: Questo stack è compilato dalla comunità e a scopo di ricerca solo. Peptide Contacts non verifica la sicurezza o l'efficacia dei stack compilati. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi protocollo di peptidi.